Who may participate

icon of 3 people with blue and teal outlineJoining a clinical trial is an important and personal decision. We hope it is one you will consider.

This study is seeking healthy male or female volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements: 

  • Willing to take a study drug 
  • Willing to take a COVID-19 rt-PCR test during visits to PCRU
  • Able to meet all study visit requirements 

There are other requirements for participation in this study. The study staff will explain these to you during the screening process.

 

Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Age
18-55 years
The age a person must be to participate in a clinical trial.
Sex
Male or Female
The sex of people who may participate in a clinical trial. Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.
Referral Bonus
Up to $200
Compensation may be provided on a loadable debit card or by paper check in US dollars. The New Haven PCRU reserves the right to determine method of payment, determine eligibility, or change or terminate this program at any time.

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

icon of a blue and teal clipboardIf this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing begins.

If you choose to participate, you will be asked to stay at our facility for 16 consecutive overnights. During your stay, you’ll receive up to 9 doses of the study drug as a tablet or liquid that you will swallow. This will be given with or without a tablet of the acid-reducing medication. The formulation you receive for each dose will be chosen at random.

All of the study procedures will be clearly explained to you during screening. Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.

Required overnight stays
16 consecutive overnights
A participant may be required to stay overnight at the PCRU for observation and study procedures. The number and length of overnight stays is determined by the design of the study.
Long-term follow up
1 phone-call
Some studies require the study team to stay in contact with the participant for a period of time after the participant completes the main part of the study. This long-term follow up is to collect additional information on the study drug over time.
How long is this study?
Up to 52 days
This does not include the time between screening and dosing, which can be up to 28 days. Participants will be in this study for up to 52 days between the first dose and final follow-up call.
Compensation
Up to $5,200 upon completion of the study
Participants in clinical trials at the PCRU receive financial compensation for their participation. The amount depends on factors like length of the stay, total number of study visits, and the nature of the study procedures.
Safety remains our top priority at the PCRU during COVID-19

Interested in participating?

Complete and submit this form, and a Pfizer Clinical Research Unit (PCRU) representative will contact you.

You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.

The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research units database. We may use this information to invite you to participate in this clinical study, as well as other current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.

Cancel